ONWARD Medical: New Shares Listed on Euronext Following Private Placement Closure
ONWARD Medical announced on Monday the closure of its private placement with institutional investors. The new shares from this operation are now admitted for trading on the regulated markets of Euronext.
Completion of Private Placement and Listing on Euronext
The neurotechnology company ONWARD Medical has completed its previously announced private placement. Starting Monday, the new shares from this operation are admitted for trading and exchange on Euronext Brussels, Euronext Amsterdam, and Euronext Paris.
ONWARD Medical: A Leader in Neurotechnology
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
ONWARD Medical positions itself as a leading company in neurotechnology, pioneering the development of therapies designed to restore movement, function, and independence in individuals suffering from spinal cord injuries and other movement disorders. The company has developed its proprietary ARC Therapy, based on decades of scientific research and clinical studies. Its ARC-EX® system is authorized for commercial sale in the United States and Europe. ONWARD Medical is also developing an investigational implantable system called ARC-IM®, designed to address several unmet needs including blood pressure instability post-spinal injury, and can be integrated with a brain-computer interface and artificial intelligence to restore thought-controlled movement. The company is headquartered in the Netherlands, with a science and engineering center in Switzerland and an office in Boston, Massachusetts, USA.
Launch of ARC-EX continues to be a resounding success...
Risks mentioned
Retard dans les approbations réglementaires pouvant affecter les délais.
Concurrence accrue dans le secteur de la neurotechnologie.
Opportunities identified
Lancement du système ARC-EX avec succès aux États-Unis.
Récupération de la demande soutenue pour la technologie de stimulation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
